GLP1R and type 2 diabetes mellitus: In conclusion, our analysis reveals substantial variability in GLP-1 RA responses in individuals with type 2 diabetes in routine clinical practice, with only a minority of individuals achieving both glycaemic and weight reductions in the first 6 months of treatment.